Biological concepts in human sodium channel epilepsies and their relevance in clinical practice
Andreas Brunklaus,Juanjiangmeng Du,Felix Steckler,Ismael I. Ghanty,Katrine M. Johannesen,Christina Dühring Fenger,Stephanie Schorge,David Baez‐Nieto,Hao‐Ran Wang,Andrew Allen,Jen Q. Pan,Holger Lerche,Henrike Heyne,Joseph D. Symonds,Sameer M. Zuberi,Stephan Sanders,Beth R. Sheidley,Dana Craiu,Heather E. Olson,Sarah Weckhuysen,Peter DeJonge,Ingo Helbig,Hilde Van Esch,Tiffany Busa,Matthieu Milh,Bertrand Isidor,Christel Depienne,Annapurna Poduri,Arthur J. Campbell,Jordane Dimidschstein,Rikke S. Møller,Dennis Lal
DOI: https://doi.org/10.1111/epi.16438
IF: 6.74
2020-03-01
Epilepsia
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>Voltage‐gated sodium channels (SCNs) share similar amino acid sequence, structure, and function. Genetic variants in the four human brain‐expressed <i>SCN</i> genes <i>SCN1A/2A/3A/8A</i> have been associated with heterogeneous epilepsy phenotypes and neurodevelopmental disorders. To better understand the biology of seizure susceptibility in <i>SCN</i>‐related epilepsies, our aim was to determine similarities and differences between sodium channel disorders, allowing us to develop a broader perspective on precision treatment than on an individual gene level alone. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We analyzed genotype‐phenotype correlations in large <i>SCN</i>‐patient cohorts and applied variant constraint analysis to identify severe sodium channel disease. We examined temporal patterns of human <i>SCN</i> expression and correlated functional data from in vitro studies with clinical phenotypes across different sodium channel disorders. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Comparing 865 epilepsy patients (504 <i>SCN1A</i>, 140 <i>SCN2A</i>, 171 <i>SCN8A</i>, four <i>SCN3A</i>, 46 copy number variation [CNV] cases) and analysis of 114 functional studies allowed us to identify common patterns of presentation. All four epilepsy‐associated <i>SCN</i> genes demonstrated significant constraint in both protein truncating and missense variation when compared to other <i>SCN</i> genes. We observed that age at seizure onset is related to <i>SCN</i> gene expression over time. Individuals with gain‐of‐function <i>SCN2A/3A/8A</i> missense variants or CNV duplications share similar characteristics, most frequently present with early onset epilepsy (<3 months), and demonstrate good response to sodium channel blockers (SCBs). Direct comparison of corresponding <i>SCN</i> variants across different <i>SCN</i> subtypes illustrates that the functional effects of variants in corresponding channel locations are similar; however, their clinical manifestation differs, depending on their role in different types of neurons in which they are expressed. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significance</h3><p>Variant function and location within one channel can serve as a surrogate for variant effects across related sodium channels. Taking a broader view on precision treatment suggests that in those patients with a suspected underlying genetic epilepsy presenting with neonatal or early onset seizures (<3 months), SCBs should be considered.</p></section>
clinical neurology